Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

IGI Laboratories and Juventio Execute Three Year Turnkey Supply Agreement

Published: Friday, February 22, 2013
Last Updated: Friday, February 22, 2013
Bookmark and Share
Agreement to manufacture and supply finished dose forms of certain cosmetic and OTC products and formulations.

IGI Laboratories, Inc. has announced that it has entered into a three year agreement with Juventio, LLC to manufacture and supply finished dose forms of certain cosmetic and OTC products and formulations owned and developed by IGI.

These products utilize innovative encapsulation technology trademarked as Novasome® for which IGI currently holds an exclusive license.

Juventio is a New Jersey based company that distributes premium non-prescription health products, in partnership with healthcare professionals.

Jason Grenfell-Gardner, President and CEO of the Company, commented, “We are excited to partner with Juventio, and utilize our existing Novasome® technology to provide turnkey manufacturing services. The utilization of our own technology and know-how enables us to achieve higher margins on these products, which brings us one step closer to achieving our goal of profitability in 2013. The agreement, which includes a total of $3.0 million of minimum purchases over the contract lifespan, is a testament to our focus to expand our higher-margin, committed contract services business.”

Tom Ford, Juventio’s CEO, notes, “The combination of IGI’s innovative technology and reliable manufacturing services makes them an ideal partner as we seek to provide health care professionals and patients with safe, effective and innovative solutions to common health issues.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

IGI Laboratories to Acquire the Assets of Alveda Pharmaceuticals
Acquisition will deliver contribution to 2015 financial results.
Thursday, October 15, 2015
IGI Completes its Sixth ANDA Filing for 2013
Company under joint drug development and commercialization agreement.
Friday, January 03, 2014
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos